Longeveron (LGVN) Debt to Equity (2021 - 2023)

Longeveron (LGVN) recorded quarterly Debt to Equity of $0.09 in Q3 2023, up 72.18% quarter-over-quarter from $0.05 in Q2 2023.

Longeveron (LGVN) Debt to Equity (2021 - 2023) Analysis & Trends

Longeveron's Debt to Equity history runs 3 years deep, the most recent figure standing at $0.09 for Q3 2023.

  • In Q3 2023, Debt to Equity changed N/A year-over-year to $0.09; the TTM figure through Sep 2023 stood at $0.09 (changed N/A YoY), while the FY2022 annual figure was $0.03, up 91.86% from the prior year.
  • Debt to Equity was $0.09 for Q3 2023 at Longeveron, up from $0.05 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.09 in Q3 2023 to a low of $0.01 in Q4 2021.
  • Historically, Debt to Equity has averaged $0.04 across 3 years, with a median of $0.03 in 2023.
  • Biggest YoY gain for Debt to Equity was 91.86% in 2022; the steepest drop was 91.86% in 2022.
  • A 3-year view of Debt to Equity shows it stood at $0.01 in 2021, then surged by 91.86% to $0.03 in 2022, then jumped by 221.21% to $0.09 in 2023.
  • The last three Debt to Equity figures came in at $0.09 (Q3 2023), $0.05 (Q2 2023), and $0.03 (Q1 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.32
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00 -

Historic Data

Download Data
DateValue
Sep 30, 2023 0.09
Jun 30, 2023 0.05
Mar 31, 2023 0.03
Dec 31, 2022 0.03
Dec 31, 2021 0.01